Dose adjustment in renal impairment
Dose adjustment may be needed in kidney disease.
Leaflet ANAGRELIDA TEVA 0.5mg capsules
- Product code:
- W64656002
- Quantity:
- 100
- Indicated for:
- essential thrombocythemia
- Route of administration:
- oral
- Substance:
- anagrelide (anticoagulant)
- ATC
- L01XX35 — Antineoplastic and immunomodulating agents | Other antineoplastic agents
Precautions:
Major drug interactions
This medicine may have important interactions with other medicines.
Additional monitoring
This medicine is subject to additional monitoring.
Breastfeeding warning
Use during breastfeeding only on medical advice.
Pregnancy warning
Use during pregnancy only on medical advice.
Bleeding risk
This medicine may increase the risk of bleeding.
Anagrelide is a medication used for the treatment of essential thrombocythemia, a hematological condition characterized by an excessive number of platelets in the blood. This condition can increase the risk of blood clot formation, leading to complications such as strokes or heart attacks. Anagrelide works by inhibiting the maturation of megakaryocytes, the precursors of platelets, thereby reducing the platelet count in the blood.
Anagrelide is administered orally, usually two to four times daily, with the dosage adjusted based on the patient's response and platelet levels.
Common side effects include headaches, dizziness, nausea, diarrhea, and palpitations. In rare cases, severe adverse reactions such as heart failure or liver function impairment may occur.
Patients taking anagrelide should undergo regular monitoring for platelet counts and signs of adverse reactions. Additionally, the medication may interact with other anticoagulant or antiplatelet therapies, requiring caution. Anagrelide is an effective option for managing essential thrombocythemia, helping to reduce the risk of thrombotic complications.
Anagrelide is administered orally, usually two to four times daily, with the dosage adjusted based on the patient's response and platelet levels.
Common side effects include headaches, dizziness, nausea, diarrhea, and palpitations. In rare cases, severe adverse reactions such as heart failure or liver function impairment may occur.
Patients taking anagrelide should undergo regular monitoring for platelet counts and signs of adverse reactions. Additionally, the medication may interact with other anticoagulant or antiplatelet therapies, requiring caution. Anagrelide is an effective option for managing essential thrombocythemia, helping to reduce the risk of thrombotic complications.
General data about ANAGRELIDA TEVA 0.5mg
- Substance:
- anagrelide
- Date of latest medicines list:
- 01-06-2026
- Product code:
- W64656002
- Concentration:
- 0.5mg
- Pharmaceutical form:
- capsules
- Quantity:
- 100
- Product type:
- Generic medicine
- Price:
- 386.18 RON
- Prescription status:
- P-RF — Medicines dispensed with a medical prescription that is retained by the pharmacy and cannot be renewed.
Concentrations available for anagrelide
- 0.5mg
- 0.75mg
- 1mg